
Enzychem Lifesciences Prepares for Phase 3 Trial in Oral Mucositis, Pursues DAC and AI Drug Development
Image for illustrative purposes / FLUX Enzychem Lifesciences is preparing to advance its lead pipeline, EC-18, into a Phase 3 trial for oral mucositis while accelerating development of next-generation pipelines, including an antibody-degrader conjugate (DAC) and an artificial int
2026-05-13











